A Roadmap for Access
We must secure sustainable markets to ensure patient access to generic and biosimilar medicines
This article first appeared in The Medicine Maker on March 22, 2021.
The Generics and Biosimilars Industry Has a Plan to Secure Our Medicines — #SecureOurMeds
The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to "#SecureOurMeds." We already produce billions of doses of medicine right here in America, and our plan ensures continued patient access through COVID and beyond.
Learn more about our path forward at: https://www.secureourmeds.org/
Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets
This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market. It is the first in a series of AAM papers that will highlight challenges to the overall sustainability of the generics and biosimilars industry.
AAM Outlines Policy Solutions for Sustained Patient Access to Generic and Biosimilar Medicines
Association for Accessible Medicines Unveils Policy Agenda for
Biden Administration and 117th Congress
Outlines Policy Solutions to Support Long-Term Sustainability of Generic and Biosimilar Medicines
New Campaign Highlights Lifesaving Role Generic Drugs Have Played in Treatment of COVID-19
Report Series Examines Threats to Patient Access and Affordability
While We Await the Vaccine, We Can Trust in Generic Drugs
This article first appeared in Managed Healthcare Executive on February 1, 2021.
AAM’s Recommendations to #SecureOurMeds
Generic and biosimilar medicines are a proven solution to lowering drug costs, and the use of these medicines saved more than $313 billion in 2019 alone. At a time of high economic insecurity, access to more-affordable generic and biosimilars means patients are more likely to fill and use a generic drug prescription.
AAM Statement on Biden’s Executive Orders to Strengthen America’s COVID Response
WASHINGTON, DC (January 21, 2020) — The Association for Accessible Medicines (AAM) strongly endorses the Biden administration’s executive orders to strengthen America’s response to the COVID pandemic. Generic medicines have been instrumental in treating COVID patients with severe conditions, serving as a bridge until the COVID vaccines are widely available. AAM’s members are ready to partner with the Biden administration to ensure reliable and predictable access to these vital therapies.
2021 Generics and Biosimilars Outlook
This article first appeared in Chain Drug Review on January 5, 2021 as Pharmacy Outlook: Dan Leonard.
Member Spotlight: Sandoz
Sandoz, the largest medicines provider in Europe and a major player globally, has a U.S. headquarters in Princeton, NJ. The Novartis division’s robust response to the COVID-19 pandemic has taken many forms:
-
Affordability. In early June, CEO Richard Saynor penned a LinkedIn post pledging:
Member Spotlight: Apotex
Based in Toronto, Canada, Apotex also operates in the United States, Mexico and India. The company employs close to 8,000 people worldwide in manufacturing, R&D and commercial operations. Its Apobiologix division focuses on biosimilars development.
Here are some of Apotex’s most recent endeavors with the biggest impact: